Presentation is loading. Please wait.

Presentation is loading. Please wait.

Progression and survival analysis.

Published byすずり しばもと Modified over 4 years ago

Similar presentations

Presentation on theme: "Progression and survival analysis."— Presentation transcript:

1 Progression and survival analysis.
Progression and survival analysis. A, Kaplan–Meier curves showing PFS time intervals measured in patients for whom the disease progressed to locoregional cutaneous/subcutaneous metastases (skin), or locoregional LN, or to distant metastases (systemic). For the calculation of LN and systemic, prior locoregional cutaneous/subcutaneous metastases were ignored. Censored events are indicated by a vertical tick. B, Kaplan–Meier analysis of OS in 24 evaluable patients. Benjamin Weide et al. Cancer Immunol Res 2014;2: ©2014 by American Association for Cancer Research

Download ppt "Progression and survival analysis."

Similar presentations

EUROCHIP PILOT STUDIES. Collection of detailed clinical information for specific tumours Describing and comparing care in representative samples of cancer.

EUROCHIP PILOT STUDIES. Collection of detailed clinical information for specific tumours Describing and comparing care in representative samples of cancer.
Neoadjuvant twice daily chemoradiotherapy for esophageal cancer: Treatment-related mortality and long-term outcomes  Stuart E. Samuels, MD, PhD, Matthew.

Neoadjuvant twice daily chemoradiotherapy for esophageal cancer: Treatment-related mortality and long-term outcomes  Stuart E. Samuels, MD, PhD, Matthew.
Oncol Res Treat 2016;39: DOI: /

Oncol Res Treat 2016;39: DOI: /
Kaplan-Meier survival curves comparing survival between both time periods according to management strategy. Survival in patients with infective endocarditis.

Kaplan-Meier survival curves comparing survival between both time periods according to management strategy. Survival in patients with infective endocarditis.
High GDF-15 Serum Levels Independently Correlate with Poorer Overall Survival of Patients with Tumor-Free Stage III and Unresectable Stage IV Melanoma 

High GDF-15 Serum Levels Independently Correlate with Poorer Overall Survival of Patients with Tumor-Free Stage III and Unresectable Stage IV Melanoma 
Frequency of JAK1 and JAK2 alterations and their association with overall survival in TCGA datasets. Frequency of JAK1 and JAK2 alterations and their association.

Frequency of JAK1 and JAK2 alterations and their association with overall survival in TCGA datasets. Frequency of JAK1 and JAK2 alterations and their association.
Prognostic significance of DDB2 in ovarian cancer.

Prognostic significance of DDB2 in ovarian cancer.
Kaplan–Meier curves of 12-month survival after an index chronic obstructive pulmonary disease-related hospitalisation according to level of moderate and.

Kaplan–Meier curves of 12-month survival after an index chronic obstructive pulmonary disease-related hospitalisation according to level of moderate and.
Phase II Study of Amrubicin Combined with Carboplatin for Thymic Carcinoma and Invasive Thymoma: North Japan Lung Cancer Group Study 0803  Akira Inoue,

Phase II Study of Amrubicin Combined with Carboplatin for Thymic Carcinoma and Invasive Thymoma: North Japan Lung Cancer Group Study 0803  Akira Inoue,
Kaplan–Meier curves for a, b) progression-free survival (PFS) and c, d) overall survival (OS) in a, c) large-cell neuroendocrine carcinoma patients and.

Kaplan–Meier curves for a, b) progression-free survival (PFS) and c, d) overall survival (OS) in a, c) large-cell neuroendocrine carcinoma patients and.
A–d) Comparison of Kaplan–Meier curves of a) progression-free survival (PFS) and c) overall survival (OS) in large-cell neuroendocrine carcinoma (LCNEC)

A–d) Comparison of Kaplan–Meier curves of a) progression-free survival (PFS) and c) overall survival (OS) in large-cell neuroendocrine carcinoma (LCNEC)
Kaplan–Meier curves of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) progression-free survival (PFS) were constructed based on.

Kaplan–Meier curves of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) progression-free survival (PFS) were constructed based on.
Survival without tracheostomy

Survival without tracheostomy
Table 2. Progression-Free Survival

Table 2. Progression-Free Survival
Kaplan–Meier curve for the time until the development of lung cancer in patients with idiopathic pulmonary fibrosis. Kaplan–Meier curve for the time until.

Kaplan–Meier curve for the time until the development of lung cancer in patients with idiopathic pulmonary fibrosis. Kaplan–Meier curve for the time until.
Tumor development of poorly immunogenic LLC and B16F10 cells modified to produce GM-CSF was markedly inhibited. Tumor development of poorly immunogenic.

Tumor development of poorly immunogenic LLC and B16F10 cells modified to produce GM-CSF was markedly inhibited. Tumor development of poorly immunogenic.
Treatment of human MCC tumors with intralesional IFNβ is associated with MHC-I upregulation. Treatment of human MCC tumors with intralesional IFNβ is associated.

Treatment of human MCC tumors with intralesional IFNβ is associated with MHC-I upregulation. Treatment of human MCC tumors with intralesional IFNβ is associated.
Kaplan–Meier survival curves of overall survival (OS) for EGFR mutant lung adenocarcinoma patients who received epidermal growth factor receptor tyrosine.

Kaplan–Meier survival curves of overall survival (OS) for EGFR mutant lung adenocarcinoma patients who received epidermal growth factor receptor tyrosine.
Kaplan–Meier survival curves of all-cause mortality in patients with idiopathic pulmonary fibrosis (IPF). Kaplan–Meier survival curves of all-cause mortality.

Kaplan–Meier survival curves of all-cause mortality in patients with idiopathic pulmonary fibrosis (IPF). Kaplan–Meier survival curves of all-cause mortality.
Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Similar presentations

Ads by Google